Quince Therapeutics Acquires Orphai, Secures $115M Upfront Financing to Fund New Pulmonary Pipeline

summarizeSummary

Quince Therapeutics acquired Orphai Therapeutics, gaining a new pulmonary disease pipeline and securing $115 million in upfront financing (up to $187 million total) to fund operations through 2028. This deal, while critical for the company's survival and strategic pivot, results in significant dilution for existing shareholders.

check_boxKey Events · M&A and Partnerships · QNCX

• Acquisition of Orphai Therapeutics

  Quince Therapeutics acquired Orphai Therapeutics, LLC, gaining its lead drug candidate LAM-001 and a pipeline focused on rare pulmonary diseases. The acquisition is intended to qualify as a tax-free reorganization.

• Significant Capital Raise

  The company secured $115 million in upfront proceeds through a private placement of Series C Non-Voting Convertible Preferred Stock and warrants, with potential for an additional $72 million upon warrant exercise. This financing is expected to fund operations through the end of 2028.

• Extreme Shareholder Dilution

  Post-financing, pre-transaction Quince equityholders will hold approximately 6.9% of the fully-diluted common stock, former Orphai equityholders will hold approximately 31.9%, and new investors will hold approximately 61.2%.

• New Preferred Stock and Authorized Share Increase Proposal

  The company filed a Certificate of Designation for Series C Preferred Stock, convertible into 1,000 common shares each. Shareholders will vote on its conversion and a proposal to increase authorized common stock from 250 million to 800 million shares.

auto_awesomeAnalysis · QNCX · Life Sciences

Quince Therapeutics has executed a transformative transaction by acquiring Orphai Therapeutics, bringing a new lead drug candidate, LAM-001, and its pulmonary disease pipeline into the company. This strategic shift is coupled with a substantial capital raise of $115 million upfront, with the potential for an additional $72 million from warrant exercises, providing a projected cash runway through the end of 2028. This financing is critical for a company that recently disclosed a drug failure and going concern doubts. However, the deal comes at a significant cost to existing shareholders, who will see their ownership diluted to approximately 6.9% of the fully-diluted common stock post-financing. The new Series C Non-Voting Convertible Preferred Stock, issued in the merger and private placement, converts at a 1:1000 ratio, effectively representing a massive increase in the common share count. The company is also proposing to increase its authorized common stock from 250 million to 800 million shares, enabling further potential dilution. While the capital infusion and new pipeline offer a lifeline and a new strategic direction, the terms are highly dilutive and the financing is priced at a discount to the current market price.